<DOC>
	<DOC>NCT01538511</DOC>
	<brief_summary>This trial is conducted in Japan. The aim of this trial is to compare biphasic insulin aspart 70 (NN2000-Mix70) in subjects with type 2 diabetes with that of biphasic insulin aspart 30 (NN-X14Mix30) in healthy volunteers.</brief_summary>
	<brief_title>Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>SUBJECTS WITH TYPE 2 DIABETES Subjects with type 2 diabetes mellitus Current treatment using intermediateacting, longacting or premixed/biphasic insulin preparation (including insulin analogues) in once or twice daily (before breakfast and dinner) treatment regimen for at least 12 weeks (a temporary use [maximum of one week in total] of rapidacting human insulin will be allowed) Age between 2069 years, both inclusive HbA1c (glycosylated haemoglobin A1c) below 9.0% Body Mass Index (BMI) 18.525.0 kg/m^2 Total daily insulin dose (per day) above 0.2 U or IU/kg body weight and below 1.0 U or IU/kg body weight HEALTHY VOLUNTEERS Japanese subjects with considered generally healthy based on medical history and physical examination Age between 2029 years, both inclusive Body Mass Index (BMI) 18.525.0 kg/m^2 Subjects with normal glucose tolerance (NGT); defined as fasting plasma glucose below 110 mg/dL and 2hour post OGTT (oral glucose tolerance test) plasma glucose below 140 mg/dL SUBJECTS WITH TYPE 2 DIABETES Proliferative retinopathy or maculopathy requiring acute treatment Impaired hepatic function Impaired renal function Serious cardiac diseases Uncontrolled hypertension Known hypoglycaemia unawareness or recurrent major hypoglycaemia Current treatment or expected at the screening to start treatment with systemic corticosteroids HEALTHY VOLUNTEERS Any clinical laboratory values deviated from the reference range at the laboratory (except for cases within physiological change) at the screening History or presence of diabetes, cancer or any clinically significant cardiac, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological, dermatological, venereal, haematological, neurological, or psychiatric diseases or disorders Subjects with a firstdegree relative with diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>